No Data
Staidson (300204.SZ): The STSP-0902 injection (used for the treatment of oligozoospermia) has obtained the Phase Ia clinical research summary report.
On May 8, Gelonghui reported that Staidson (300204.SZ) announced that recently, Staidson (Peking) Biopharmaceutical Co., Ltd. obtained the summary report of the Phase Ia clinical research for STSP-0902 injection for the treatment of oligospermia. In healthy subjects, within the designed dosage range, the safety and tolerance of a single subcutaneous injection of STSP-0902 were good, displaying essentially linear pharmacokinetic characteristics, with no reports of ADA positivity, indicating a low risk of immunogenicity. The results of this trial support further clinical research for STSP-0902 injection.
Shu Taishen: Report for the first quarter of 2025
Staidson (300204.SZ): Net loss of 2.335 million yuan in the first quarter.
Gelonghui reported on April 24 that Staidson (300204.SZ) announced its first quarter report for 2025, with revenue of 63.214 million yuan, a year-on-year decrease of 33.45%; the net income attributable to shareholders of the listed company was -2.335 million yuan; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -3.3767 million yuan; the basic EPS was 0.00 yuan.
"In the best development period in history"? Staidson's Chairman faced investors with a "soul-searching question" | Coverage of the Earnings Conference
① After several years of losses, Staidson's Chairman Zhou Zhiwen faced multiple questions during the Earnings Conference held today; ② The company's senior management also responded to questions regarding the future pace of research and development investments.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Shu Taishen: 2024 Annual Report